PKN605-AF
A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral PKN605 in participants with atrial fibrillation
- Stage
- inclusie
- Medicine
- PKN605
- Population
- Ritme
- Phase
- II
- First Patient In
- 15 December 2025
- Last Patient In
- 1 July 2027
- Last Patient Last Visit
- 15 May 2028
Inclusion period, 313 days remaining
Study Director
dr. M.E.W. Hemels
Cardioloog
Office Contact
